1
|
Dourson M, Gadagbui B. The Dilemma of perfluorooctanoate (PFOA) human half-life. Regul Toxicol Pharmacol 2021; 126:105025. [PMID: 34400261 DOI: 10.1016/j.yrtph.2021.105025] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 07/14/2021] [Accepted: 07/30/2021] [Indexed: 11/21/2022]
Abstract
Disparity in the results from human observational and clinical studies is not uncommon, but risk assessment efforts often judge one set of data more relevant with the loss of valuable information. The assessment for perfluorooctanoate (PFOA) is a good example of this problem. The estimation of its safe dose is disparate among government groups due in part to differences in understanding of its half-life in humans. These differences are due in part to incomplete information on sources of exposure in the human observational half-life studies, which have been routinely acknowledged, but until recently not well understood. Exposure information is thus critical in understanding, and possibly resolving, this disparity in PFOA safe dose, and potentially for disparities with similar chemistries when both human observational and clinical findings are available. We explore several hypotheses to explain this disparity in PFOA half-life from human observational studies in light of findings of a clinical study in humans and relevant exposure information from a recent international meeting of the Society of Toxicology and Environmental Chemistry (SETAC). Based on information from both human observational studies and clinical data, we proposed a range for the half-life for PFOA of 0.5-1.5 years, which would likely raise many existing regulatory safe levels if all other parameters stayed the same.
Collapse
|
2
|
Prikhozhdenko ES, Gusliakova OI, Kulikov OA, Mayorova OA, Shushunova NA, Abdurashitov AS, Bratashov DN, Pyataev NA, Tuchin VV, Gorin DA, Sukhorukov GB, Sindeeva OA. Target delivery of drug carriers in mice kidney glomeruli via renal artery. Balance between efficiency and safety. J Control Release 2021; 329:175-190. [PMID: 33276016 DOI: 10.1016/j.jconrel.2020.11.051] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 11/11/2020] [Accepted: 11/24/2020] [Indexed: 12/12/2022]
Abstract
Targeting drug delivery systems is crucial to reducing the side effects of therapy. However, many of them are lacking effectiveness for kidney targeting, due to systemic dispersion and accumulation in the lungs and liver after intravenous administration. Renal artery administration of carriers provides their effective local accumulation but may cause irreversible vessel blockage. Therefore, the combination of the correct administration procedure, suitable drug delivery system, selection of effective and safe dosage is the key to sparing local therapy. Here, we propose the 3-μm sized fluorescent capsules based on poly-L-arginine and dextran sulfate for targeting the kidney via a mice renal artery. Hemodynamic study of the target kidney in combination with the histological analysis reveals a safe dose of microcapsules (20 × 106), which has not lead to irreversible pathological changes in blood flow and kidney tissue, and provides retention of 20.5 ± 3% of the introduced capsules in the renal cortex glomeruli. Efficacy of fluorescent dye localization in the target kidney after intra-arterial administration is 9 times higher than in the opposite kidney and after intravenous injection. After 24 h microcapsules are not observed in the target kidney when the safe dose of carriers is being used but a high level of fluorescent signal persists for 48 h indicating that fluorescent cargo accumulation in tissues. Injection of non-safe microcapsule dose leads to carriers staying in glomeruli for at least 48 h which has consequences of blood flow not being restored and tissue damage being observed in histology.
Collapse
Affiliation(s)
| | - Olga I Gusliakova
- Saratov State University, 83 Astrakhanskaya str., Saratov 410012, Russia
| | - Oleg A Kulikov
- Ogarev Mordovia State University, 68 Bolshevistskaya str., Saransk 430005, Russia
| | - Oksana A Mayorova
- Saratov State University, 83 Astrakhanskaya str., Saratov 410012, Russia
| | | | - Arkady S Abdurashitov
- Skolkovo Institute of Science and Technology, Skolkovo Innovation Center, 3 Nobel str., Moscow 143005, Russia
| | - Daniil N Bratashov
- Saratov State University, 83 Astrakhanskaya str., Saratov 410012, Russia
| | - Nikolay A Pyataev
- Ogarev Mordovia State University, 68 Bolshevistskaya str., Saransk 430005, Russia
| | - Valery V Tuchin
- Saratov State University, 83 Astrakhanskaya str., Saratov 410012, Russia; National Research Tomsk State University, 36 Lenin Ave., Tomsk 634050, Russia
| | - Dmitry A Gorin
- Skolkovo Institute of Science and Technology, Skolkovo Innovation Center, 3 Nobel str., Moscow 143005, Russia
| | - Gleb B Sukhorukov
- Skolkovo Institute of Science and Technology, Skolkovo Innovation Center, 3 Nobel str., Moscow 143005, Russia; School of Engineering and Materials Science, Queen Mary University of London, Mile End, Eng, 215, London E1 4NS, United Kingdom
| | - Olga A Sindeeva
- Saratov State University, 83 Astrakhanskaya str., Saratov 410012, Russia; Skolkovo Institute of Science and Technology, Skolkovo Innovation Center, 3 Nobel str., Moscow 143005, Russia.
| |
Collapse
|